Maxcyte Inc., of Gaithersburg, Md., said it presented preclinical data at the American Society of Gene & Cell Therapy meeting in Chicago, describing how nonviral cell engineering technology was used for CRISPR-mediated gene correction of a mutation within the hemoglobin gene of cells from a sickle cell disease (SCD) patient.